Mavrilimumab

N/A

Report date: 2026/04/23 20:00:25

Base Information

Drug NameMavrilimumab
Drug Alias Namemavrilimumabum玛弗利木单抗Anti-GM-CSFR monoclonal antibodyCAM-3001KPL-301 +[7] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionGranulocyte-macrophage colony-stimulating factor receptor subunit alpha inhibitors
TargetsGranulocyte-macrophage colony-stimulating factor receptor subunit alpha
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Giant Cell ArteritisArthritis, Rheumatoid +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[36] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesCsl Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHuadong Medicine Co LtdKiniksa Pharmaceuticals International PLCKiniksa Pharmaceuticals Ltd +[4] 
Inactive CompaniesMedimmune LtdVirginia Commonwealth UniversityMedimmune Llc
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsGiant Cell ArteritisArthritis, RheumatoidPneumonia

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG